{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T06:03:10Z","timestamp":1782540190067,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16K19710"],"award-info":[{"award-number":["16K19710"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jdermsci.2021.04.004","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T03:48:32Z","timestamp":1618544912000},"page":"116-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Fingolimod ameliorates imiquimod-induced psoriasiform dermatitis by sequestrating interleukin-17-producing ?d T cells in secondary lymph nodes"],"prefix":"10.1016","volume":"102","author":[{"given":"Iori","family":"Okura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Mitsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jdermsci.2021.04.004_bib0005","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"7130","key":"10.1016\/j.jdermsci.2021.04.004_bib0010","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"issue":"Suppl 2","key":"10.1016\/j.jdermsci.2021.04.004_bib0015","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jdermsci.2021.04.004_bib0020","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.clindermatol.2006.07.006","article-title":"Psoriasis and psoriatic arthritis: clinical features and disease mechanisms","volume":"24","author":"Myers","year":"2006","journal-title":"Clin. Dermatol."},{"issue":"6","key":"10.1016\/j.jdermsci.2021.04.004_bib0025","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J. Invest. Dermatol."},{"issue":"9993","key":"10.1016\/j.jdermsci.2021.04.004_bib0030","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jdermsci.2021.04.004_bib0035","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.jdermsci.2021.04.004_bib0040","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9625","key":"10.1016\/j.jdermsci.2021.04.004_bib0045","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jdermsci.2021.04.004_bib0050","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"16","key":"10.1016\/j.jdermsci.2021.04.004_bib0055","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10091","key":"10.1016\/j.jdermsci.2021.04.004_bib0060","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"issue":"64","key":"10.1016\/j.jdermsci.2021.04.004_bib0065","first-page":"213","article-title":"A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya)","volume":"12","author":"Chun","year":"2011","journal-title":"Discov. Med."},{"key":"10.1016\/j.jdermsci.2021.04.004_bib0070","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0960-894X(95)00127-F","article-title":"Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1, 3-propanediols: discovery of a novel immunosuppressant, FTY 720","volume":"5","author":"Adachi","year":"1995","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"24","key":"10.1016\/j.jdermsci.2021.04.004_bib0075","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","article-title":"The immune modulator FTY720 targets sphingosine 1-phosphate receptors","volume":"277","author":"Brinkmann","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"6972","key":"10.1016\/j.jdermsci.2021.04.004_bib0080","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature02284","article-title":"Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1","volume":"427","author":"Matloubian","year":"2004","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jdermsci.2021.04.004_bib0085","first-page":"11","article-title":"Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus","volume":"3","author":"Chiba","year":"2006","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jdermsci.2021.04.004_bib0090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13075-015-0909-6","article-title":"The CII-specific autoimmune T-cell response develops in the presence of FTY720 but is regulated by enhanced Treg cells that inhibit the development of autoimmune arthritis","volume":"18","author":"Miller","year":"2016","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"10.1016\/j.jdermsci.2021.04.004_bib0095","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.4049\/jimmunol.170.7.3662","article-title":"Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells","volume":"170","author":"Xie","year":"2003","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.jdermsci.2021.04.004_bib0100","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.4049\/jimmunol.178.6.3437","article-title":"Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3","volume":"178","author":"Maeda","year":"2007","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.jdermsci.2021.04.004_bib0105","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"van der Fits","year":"2009","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.jdermsci.2021.04.004_bib0110","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.4049\/jimmunol.1101817","article-title":"Epidermal CCR6+ gammadelta T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis","volume":"187","author":"Mabuchi","year":"2011","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.jdermsci.2021.04.004_bib0115","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.4049\/jimmunol.1103173","article-title":"Blockade of phosphatidylinositol 3-kinase PI3Kdelta or PI3Kgamma reduces IL-17 and ameliorates imiquimod-induced psoriasis-like dermatitis","volume":"189","author":"Roller","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.jdermsci.2021.04.004_bib0120","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1038\/ncomms8687","article-title":"Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from gammadelta-T cells","volume":"6","author":"Shibata","year":"2015","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.jdermsci.2021.04.004_bib0125","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","article-title":"Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation","volume":"35","author":"Cai","year":"2011","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.jdermsci.2021.04.004_bib0130","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4049\/jimmunol.1102224","article-title":"IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice","volume":"188","author":"Van Belle","year":"2012","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.jdermsci.2021.04.004_bib0135","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jdermsci.2019.07.006","article-title":"Anti-IL-17A and IL-23p19 antibodies but not anti-TNFalpha antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis","volume":"95","author":"Shimizu","year":"2019","journal-title":"J. Dermatol. Sci."},{"issue":"4","key":"10.1016\/j.jdermsci.2021.04.004_bib0140","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1248\/bpb.b17-00939","article-title":"Validating a selective S1P1 receptor modulator Syl930 for psoriasis treatment","volume":"41","author":"Ji","year":"2018","journal-title":"Biol. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.jdermsci.2021.04.004_bib0145","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jdermsci.2013.03.006","article-title":"Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis","volume":"71","author":"Schaper","year":"2013","journal-title":"J. Dermatol. Sci."},{"issue":"3","key":"10.1016\/j.jdermsci.2021.04.004_bib0150","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.intimp.2010.10.005","article-title":"Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-beta in mouse experimental autoimmune encephalomyelitis","volume":"11","author":"Chiba","year":"2011","journal-title":"Int. Immunopharmacol."},{"issue":"26","key":"10.1016\/j.jdermsci.2021.04.004_bib0155","doi-asserted-by":"crossref","first-page":"8046","DOI":"10.1073\/pnas.1508990112","article-title":"Inflammation induces dermal V?4+ ?dT17 memory-like cells that travel to distant skin and accelerate secondary IL-17-driven responses","volume":"112","author":"Ram\u00edrez-Valle","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jdermsci.2021.04.004_bib0160","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.jdermsci.2021.04.004_bib0165","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jaad.2013.12.036","article-title":"Interleukin 17A: toward a new understanding of psoriasis pathogenesis","volume":"71","author":"Lynde","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.jdermsci.2021.04.004_bib0170","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1346-8138.14139","article-title":"Pathogenesis of psoriasis and development of treatment","volume":"45","author":"Ogawa","year":"2018","journal-title":"J. Dermatol."},{"issue":"5","key":"10.1016\/j.jdermsci.2021.04.004_bib0175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.jdermsci.2021.04.004_bib0180","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/jid.2014.98","article-title":"IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing gammadelta T cells","volume":"134","author":"Yoshiki","year":"2014","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.jdermsci.2021.04.004_bib0185","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/intimm\/dxn050","article-title":"Sphingosine-1-phosphate receptor type-1 agonism impairs blood dendritic cell chemotaxis and skin dendritic cell migration to lymph nodes under inflammatory conditions","volume":"20","author":"Gollmann","year":"2008","journal-title":"Int. Immunol."},{"issue":"8","key":"10.1016\/j.jdermsci.2021.04.004_bib0190","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/jid.2008.454","article-title":"Topical application of sphingosine-1-phosphate and FTY720 attenuate allergic contact dermatitis reaction through inhibition of dendritic cell migration","volume":"129","author":"Reines","year":"2009","journal-title":"J. Invest. Dermatol."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181121000773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181121000773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:51:35Z","timestamp":1760331095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181121000773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0923181121000773"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2021.04.004","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fingolimod ameliorates imiquimod-induced psoriasiform dermatitis by sequestrating interleukin-17-producing ?d T cells in secondary lymph nodes","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2021.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}